Trimetazidine for Early Hypertrophic Cardiomyopathy 10/27/25
Welcome to Cardiology Today â Recorded October 27, 2025. This episode summarizes 5 key cardiology studies on topics like hypertensive disorders of pregnancy and pathogenic variant. Key takeaway: Trimetazidine for Early Hypertrophic Cardiomyopathy.
Article Links:
Article 1: Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study. (Cardiovascular research)
Article 2: Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats. (Cardiovascular research)
Article 3: The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage. (Cardiovascular research)
Article 4: YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells. (Cardiovascular research)
Article 5: Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial. (Cardiovascular research)
Full episode page: https://podcast.explainheart.com/podcast/trimetazidine-for-early-hypertrophic-cardiomyopathy-10-27-25/
đ Featured Articles
Article 1: Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40911402
Summary: The REMA.I.N.-3 study was a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial. It assessed the efficacy and safety of recaticimab, a new humanized anti-Proprotein Convertase Subtilisin/Kexin type 9 antibody. This drug targets reduction of low-density lipoprotein cholesterol levels in adults with poorly controlled heterozygous familial hypercholesterolaemia. This research provides crucial data regarding a potential new therapeutic agent for this genetic disorder.
Article 2: Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40878014
Summary: This study investigated the effects of iron deficiency anemia on maternal hemodynamics and cardiac function during pregnancy. Researchers utilized pregnant spontaneously hypertensive rats and normotensive controls to understand how iron deficiency interacts with hypertensive disorders of pregnancy. This research is critical for determining whether iron deficiency ameliorates or exacerbates maternal cardiovascular dysfunction in these high-risk pregnancies. Establishing this relationship could inform better management strategies for pregnant patients.
Article 3: The pioneer factor, ETV2, regulates networks to specify the embryonic endothelial lineage.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40832854
Summary: This study elucidated the role of E.T.V.2, a pioneer transcription factor, in specifying the embryonic endothelial lineage. Researchers uncovered the specific transcriptional and epigenetic changes orchestrated by E.T.V.2 to promote hematoendothelial lineage development. Concurrently, E.T.V.2 was shown to suppress other mesodermal cell fates, precisely directing differentiation. This fundamental research significantly advances our understanding of cardiovascular development and lineage specification, offering potential avenues for regenerative strategies.
Article 4: YY1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A RNA modifications in vascular smooth muscle cells.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40795179
Summary: modifications in vascular smooth muscle cells. This study established that the transcription factor Y.Y.1 directly regulates vascular resistance and blood pressure dynamics. Researchers demonstrated that Y.Y.1 achieves this control through epigenetic modulation of m6A R.N.A. modifications within vascular smooth muscle cells. This work confirms Y.Y.1’s direct role in vasoreactivity, extending previous genome-wide association study findings. These discoveries provide crucial understanding of blood pressure regulation and open new avenues for therapeutic intervention in hypertension.
Article 5: Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial.
Journal: Cardiovascular research
PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40601822
Summary: The E.N.E.R.G.Y. trial investigated whether trimetazidine dihydrochloride therapy corrects reduced myocardial external efficiency in individuals carrying a hypertrophic cardiomyopathy pathogenic variant. This double-blind, placebo-controlled study focused on pre-clinical individuals who possessed the genetic variant but had not yet developed a hypertrophic cardiomyopathy phenotype. The research aimed to determine if this metabolic treatment could address a key pathomechanism thought to contribute to disease onset and progression. Establishing such an effect could support early pharmacological intervention to modify the disease course in at-risk individuals.
đ Transcript
Today’s date is October 27, 2025. Welcome to Cardiology Today. Here are the latest research findings.
Article number one. Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study. The REMA.I.N.-3 study was a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial. It assessed the efficacy and safety of recaticimab, a new humanized anti-Proprotein Convertase Subtilisin/Kexin type 9 antibody. This drug targets reduction of low-density lipoprotein cholesterol levels in adults with poorly controlled heterozygous familial hypercholesterolaemia. This research provides crucial data regarding a potential new therapeutic agent for this genetic disorder.
Article number two. Effects of iron deficiency anaemia on maternal haemodynamics and cardiac function in pregnant spontaneously hypertensive rats. This study investigated the effects of iron deficiency anemia on maternal hemodynamics and cardiac function during pregnancy. Researchers utilized pregnant spontaneously hypertensive rats and normotensive controls to understand how iron deficiency interacts with hypertensive disorders of pregnancy. This research is critical for determining whether iron deficiency ameliorates or exacerbates maternal cardiovascular dysfunction in these high-risk pregnancies. Establishing this relationship could inform better management strategies for pregnant patients.
Article number three. The pioneer factor, E.T.V.2, regulates networks to specify the embryonic endothelial lineage. This study elucidated the role of E.T.V.2, a pioneer transcription factor, in specifying the embryonic endothelial lineage. Researchers uncovered the specific transcriptional and epigenetic changes orchestrated by E.T.V.2 to promote hematoendothelial lineage development. Concurrently, E.T.V.2 was shown to suppress other mesodermal cell fates, precisely directing differentiation. This fundamental research significantly advances our understanding of cardiovascular development and lineage specification, offering potential avenues for regenerative strategies.
Article number four. Y.Y.1 regulates vascular resistance and blood pressure dynamics through epigenetic control of m6A R.N.A. modifications in vascular smooth muscle cells. This study established that the transcription factor Y.Y.1 directly regulates vascular resistance and blood pressure dynamics. Researchers demonstrated that Y.Y.1 achieves this control through epigenetic modulation of m6A R.N.A. modifications within vascular smooth muscle cells. This work confirms Y.Y.1’s direct role in vasoreactivity, extending previous genome-wide association study findings. These discoveries provide crucial understanding of blood pressure regulation and open new avenues for therapeutic intervention in hypertension.
Article number five. Effect of trimetazidine dihydrochloride therapy on myocardial external efficiency in pre-clinical individuals with a hypertrophic cardiomyopathy pathogenic variant: results of the ENERGY trial. The E.N.E.R.G.Y. trial investigated whether trimetazidine dihydrochloride therapy corrects reduced myocardial external efficiency in individuals carrying a hypertrophic cardiomyopathy pathogenic variant. This double-blind, placebo-controlled study focused on pre-clinical individuals who possessed the genetic variant but had not yet developed a hypertrophic cardiomyopathy phenotype. The research aimed to determine if this metabolic treatment could address a key pathomechanism thought to contribute to disease onset and progression. Establishing such an effect could support early pharmacological intervention to modify the disease course in at-risk individuals.
Thank you for listening. Don’t forget to subscribe.
đ Keywords
hypertensive disorders of pregnancy, pathogenic variant, Proprotein Convertase Subtilisin/Kexin type 9, trimetazidine dihydrochloride, pioneer transcription factor, epigenetic regulation, embryonic development, hematoendothelial lineage, hypertension, Y.Y.1, E.N.E.R.G.Y. trial, spontaneously hypertensive rats, low-density lipoprotein cholesterol, blood pressure, pre-clinical H.C.M., E.T.V.2, m6A R.N.A. modifications, hypertrophic cardiomyopathy, iron deficiency anemia, heterozygous familial hypercholesterolaemia, Phase 3 study, vascular smooth muscle cells, vascular resistance, myocardial external efficiency, endothelial lineage, cardiac function, recaticimab, maternal hemodynamics.
âšī¸ About
Concise summaries of cardiovascular research for professionals.
Subscribe âĸ Share âĸ Follow